OP-162 [AJC » Acute Coronary Syndromes] Enhanced S100A9 and S100A12 Expression in Acute Coronary Syndrome

Buyukterzi, Zafer; Can, Ummugulsum; Alpaydın, Mehmet Sertaç; Güzelant, Asuman; Karaarslan, Sukru

doi:10.1016/j.amjcard.2017.03.078

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S100A8/A9 was found to be elevated in patients with cardiovascular disease, particularly in AMI. 9,12,20 Further studies revealed that the S100A8/A9 complex may be involved in the inflammatory process of coronary atherosclerotic plaques and correlates with a vulnerable plaque phenotype; immune-double staining clearly showed that the S100A8/A9 complex was expressed in infiltrated neutrophils and some macrophages in patients with unstable angina, while the S100A8/A9-positive areas were significantly higher in patients with unstable angina than in those with stable angina. 21 S100A8/A9 also plays a pivotal role in arterial embolism [22][23][24][25] on account of the vicious inflammation/thrombosis cycle.…”

Section: Discussionmentioning

confidence: 99%

“…7 Recently, emerging evidence revealed that S100A8/A9 levels are associated with the severity of atherosclerosis and vulnerable plaque phenotypes, 8,9 abnormal platelet aggregation, and arterial thrombosis. [9][10][11][12] Therefore, the goal of this observational study was to characterize the association between serum levels of S100A8/A9 and the development of VLST.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Association Between S100A8/A9 and the Development of Very Late Stent Thrombosis in Patients With Acute Myocardial Infarction

Wang

Guan

Zhang

et al. 2020

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Very late stent thrombosis (VLST) is a rare but serious complication following percutaneous coronary intervention (PCI). S100A8/A9 plays an important role in thrombosis through modulating the inflammatory response. This observational study aimed to reveal the association between S100A8/A9 and VLST. Continuous blood samples were collected from patients at both the time of index PCI for acute myocardial infarction (AMI) and the time of PCI for VLST (VLST group) or follow-up coronary angiography (AMI group). In all, 56 patients were selected in each group from a cohort of 8476 patients and other 112 individuals who underwent health checkups (normal control [NC] group) were selected as controls. Serum levels of S100A8/A9 and high sensitivity C-reactive protein (hs-CRP) were tested and compared. The mean level of S100A8/A9 was 3754.4 ± 1688.9 ng/mL during index PCI and increased to 5517.8 ± 2650.9 ng/mL at the time of VLST; in the AMI group, S100A8/A9 level was 2434.9 ± 1243.4 ng/mL during index PCI and decreased to 1568.2 ± 772.1 ng/mL during follow-up, similar to that detected in the NC group (1618.2 ± 641.4 ng/mL). Of note, S100A8/A9 levels showed significant increases during VLST when compared to its own levels during index PCI, which was different from the changes of hs-CRP. Higher serum levels of S100A8/A9 are associated with the development of VLST.

show abstract